Open company graph database — free web & API
Login

Medinet Corporation

株式会社メディネットMEDINET Co., Ltd.Alias
Ticker
Listed market
TYO
Country
Japan
Employees (consolidated)
107
Related companies
0
§01

Basic information

BASIC
Head office
9th Floor, TRC Center Building, 6-1-1 Heiwajima, Ota-ku, Tokyo 143-0006, Japan
Chief executive
Katsunao Kubushiro
Capital
5,102,000,000  (51 100 million)
Employees (non-consolidated)
107 people
Employees (consolidated)
107 people
Start date
1995-10-17
End date
§02

Websites

1 DOMAINS
§03

Business

7
CDMO BusinessValue Chain BusinessAutologous Cancer Tissue BankRegenerative Medicine Products BusinessManufacturing of Specific Cell Processing ProductsCell Processing BusinessImmunotherapy
§04

Related companies

0 COMPANIES

—

§05

Network

NETWORK
Drag to move · click to open
§06

History

99 EVENTS

Established Medinet Corporation (capital: 10 million yen) in Nish-Shimbashi, Minato-ku, Tokyo, aiming to provide new medical services based on preventive medicineSources

Founded in Nishi-Shimbashi, Minato-ku, Tokyo, aiming to provide new medical support business in preventive medicine (capital: JPY10 million).Sources

Established the Molecular Immunology Research Institute in Setagaya-ku, Tokyo, installed a cell processing facility (Seta CPC) for Seta Clinic, and launched comprehensive immune cell therapy support servicesSources

Established the Institute of Molecular Immunology in Seta, Setagaya-ku, Tokyo, built the Cell Processing Center for Seta Clinic (Seta CPC), and began offering its core business, Immuno-Cell Therapy Total Support Service.Sources

Relocated headquarters to Shinbashi, Minato-ku, TokyoSources

Relocated its Head Office to Shimbashi, Minato-ku, Tokyo.Sources

Certified under theSources

Approved by the Ministry of Health, Labour and Welfare for the 'Project for development of new business fields' under the Act for Facilitating the Creation of New Business.Sources

Ministry of Health, Labour and Welfare approved "Project for development of new business fields" under the Act for Facilitating the Creation of New Business.Sources

Relocated headquarters to Shin-Yokohama, Kohoku Ward, Yokohama City, established a cell processing facility (Shin-Yokohama CPC1) for contracted medical institutions, and launched comprehensive immune cell therapy support services.Sources

Relocated its Head Office to Shin-Yokohama, Kohoku-ku, Yokohama, constructed Shin-Yokohama CPC1, and started providing Immuno-Cell Therapy Total Support Service to contracted Medical Institutions.Sources

Established an advanced medical research institute in Kohoku Ward, Yokohama City, Kanagawa Prefecture.Sources

Established the Institute of Medical Science in Kohoku-ku, Yokohama-shi, Kanagawa.Sources

Expanded the cell processing facility (Shin-Yokohama CPC2) for contracted medical institutions.Sources

Established Shin-Yokohama CPC2 for contracted medical institutions.Sources

Established a research and development center in Tamagawa-dai, Setagaya Ward, Tokyo, transferred the Molecular Immunology Institute and the Advanced Medical Research Institute to the same center, and renamed the Advanced Medical Research Institute to the "Institute of Molecular Genetics."Sources

Newly established the Research and Development Center at Tamagawadai, Setagaya-ku, Tokyo. Transferred the Institute of Molecular Immunology and the Institute of Medical Science to the new institute, renaming the latter to 'Institute of Molecular Genetics'.Sources

Established a research and development center in Tamagawa-dai, Setagaya-ku, Tokyo, relocating the Molecular Immunology Research Institute and the Advanced Medical Research Institute within the same center, and renamed the Advanced Medical Research Institute to the "Molecular Genetics Research Institute."Sources

Opened an Osaka branch in Esaka-cho, Suita City, Osaka Prefecture, installed a cell processing facility (Osaka CPC) for contracted medical institutions, and launched comprehensive immune cell therapy support services.Sources

Established Osaka Office in Esaka-cho, Suita-shi, Osaka, built Osaka CPC, and began providing Immuno-Cell Therapy Total Support Service to contracted medical institutions.Sources

Received the 1st 'Courageous Management Award' sponsored by the Tokyo Chamber of Commerce and Industry.Sources

Received 1st "Courageous Management Award" sponsored by the Tokyo Chamber of Commerce and Industry.Sources

Established Fukuoka Office in Hakata-ku, Fukuoka City, built Fukuoka CPC, and began providing Immuno-Cell Therapy Total Support Service to contracted medical institutions. Shares listed on the Tokyo Stock Exchange (Mothers: 2370).Sources

Established Fukuoka Office in Hakata-ku, Fukuoka-city, constructed Fukuoka CPC, and started providing Immuno-Cell Therapy Total Support Service to contracted Medical Institutions. : MEDINET's shares were listed on Tokyo Stock Exchange (Mothers: 2370) (as of Oct. 8, 2003).Sources

Listed shares on the Tokyo Stock Exchange Mothers Market.Sources

Obtained ISO9001 certification for the cell medical support business.Sources

ISO 9001 certification for quality management of cell culturing and processing obtained from the International Organization for Standardization.Sources

Merged the "Institute of Molecular Immunology" and the "Institute of Molecular Genetics," and renamed the research and development center to the "Institute of Advanced Medical Science."Sources

Amalgamated the Institute of Molecular Immunology and the Institute of Molecular Genetics, and renamed the Research and Development Center to 'Medinet Medical Institute.'Sources

Amalgamated the Institute of Molecular Immunology and the Institute of Molecular Genetics, and renamed the Research and Development Center to "Medinet Medical Institute.".Sources

Launched Japan's first therapeutic cancer tissue storage service, the "Self Cancer Tissue Bank" service.Sources

Started providing new cancer tissue storage service Self Cancer Cell Depository™.Sources

Established a cell processing facility (UTokyo 22nd Century Medical Center CPC) within the 22nd Century Medical Center of the University of Tokyo Hospital for the Department of Immuno-Cell Therapy (Immuno-Cell Therapy Division) and launched comprehensive immune cell therapy support services.Sources

Constructed Tokyo University 22nd Century Medical and Research Center CPC, and started providing Immuno-Cell Therapy Total Support Service to the 'Department of Immunotherapeutics' established inside the 22nd Century Medical and Research Center in the University of Tokyo Hospital.Sources

Established a cell processing facility (Tokyo University 22nd Century Medical Center CPC) within the 22nd Century Medical Center of the University of Tokyo Hospital for the "Department of Immunocyte Therapy (Immunocyte Therapy Division)" and started comprehensive immune cell therapy support services.Sources

Constructed Tokyo University 22nd Century Medical and Research Center CPC, and started providing Immuno-Cell Therapy Total Support Service to the "Department of Immunotherapeutics" established inside the 22nd Century Medical and Research Center in the University of Tokyo Hospital.Sources

Signed a licensing agreement with Osaka Medical Center for Health and Welfare, a National Hospital Organization, to provide technical support for the implementation of immune cell therapy.Sources

Concluded a license agreement with the National Hospital Organization Osaka Medical Center for immuno-cell therapy technological support at the center.Sources

Integrated the research and development facility into the Advanced Medical Science Research Institute in Setagaya, Tokyo, and renamed it "Research and Development Center."Sources

Amalgamated the research and development facility with the Medinet Medical Institute in Setagaya-ku, Tokyo, and renamed it to 'Research and Development Center.'Sources

Amalgamated the research and development facility with the Medinet Medical Institute in Setagaya-ku, Tokyo, and renamed it to "Research and Development Center.".Sources

Established Medical Business Management Institute Inc.Sources

Established Institute of Medical Service Management, Inc.Sources

Started comprehensive immune cell therapy support services for Kyushu University Center for Advanced Medical Innovation.Sources

Started Providing Immuno-Cell Therapy Total Support Service to Kyushu University's Center for Advanced Medical Innovation.Sources

Established a joint research division "Advanced Cell Therapy Research Division" at Kyushu University Center for Advanced Medical Innovation.Sources

Established the cooperative research department 'Department of Advanced Molecular and Cell Therapy' in Kyushu University Center for Advanced Medical Innovation.Sources

Established the cooperative research department "Department of Advanced Molecular and Cell Therapy" in Kyushu University Center for Advanced Medical Innovation.Sources

Entrusted with some operations related to the third-party advanced medical care (high-level medical care) conducted by UTokyo Hospital.Sources

Started providing its service to the University of Tokyo Hospital which provides autologous γδT lymphocytes in patients with non-small cell lung cancer as advanced medical treatment.Sources

Started providing NK cell therapy technology.Sources

Established a subsidiary, MedCell Inc., to work on a new business "Cell Medical Products Business."Sources

Established a cell culture processing facility for regenerative and cell medicine (Shinagawa CPF) in Shinagawa, Tokyo.Sources

Established a wholly owned subsidiary 'MEDcell Co., Ltd.', for the Cell Medicinal Product Business. For expansion of the 'Contract Cell Manufacturing Business,' established Cell Processing Facility for regenerative medicine and cell therapy in Shinagawa-ku, Tokyo (Shinagawa CPF).Sources

Established a subsidiary, Medcell Co., Ltd., to pursue a new business "Cell Medical Products Business": aiming to expand the new business "Cell Processing Business," and set up a cell culture processing facility (Shinagawa CPF) in Shinagawa-ku, Tokyo for regenerative and cell medical use.Sources

Established a wholly owned subsidiary "MEDcell Co., Ltd.", for the Cell Medicinal Product Business. For expansion of the "Contract Cell Manufacturing Business," established Cell Processing Facility for regenerative medicine and cell therapy in Shinagawa-ku, Tokyo (Shinagawa CPF).Sources

Obtained manufacturing license for specific cell processed products at Shinagawa CPF.Sources

Obtained license for the manufacture of specified cell products in Shinagawa CPF.Sources

Fully relocated research and development functions from Setagaya, Tokyo, to the headquarters.Sources

Transferred the entire R&D function from Tamagawadai, Setagaya-ku, Tokyo to its Head Office.Sources

Entrusted with cell processing operations at Ibaraki Prefectural Children's Hospital.Sources

Contracted cell processing business at Ibaraki Children's Hospital.Sources

Signed a contract with the General Incorporated Foundation, Health and Medical Science Association, regarding the manufacturing of specific cell processed products.Sources

Agreement with the Kenkoigaku Association on the manufacture of specified cell products.Sources

Obtained manufacturing licenses for specific cell processed products at Shin-Yokohama Cell Culture Processing Facility and Osaka Cell Culture Processing Facility.Sources

Signed a contract with Kowa Central Clinic regarding the manufacturing of specific cell processed products.Sources

Received regulatory approval to manufacture specified cell products at its Shin-Yokohama Cell Processing Center and Osaka Cell Processing Center.Sources

Agreement with Miwa Central Clinic regarding manufacturing of specified cell products.Sources

Signed a licensing agreement with Histogenics for self-cultured cartilage "NeoCart®."Sources

Entered into license agreement with Histogenics Corporation for Development and Commercialization of NeoCart for the Japanese Market.Sources

Signed a joint development agreement with the National Hospital Organization to obtain approval for manufacturing and sales of dendritic cell vaccines targeting adult T-cell leukemia as regenerative medicine products.Sources

Concluded a joint development agreement with the National Hospital Organization with the goal of obtaining approval to manufacture and sell ATL-DC-101, a dendritic cell vaccine for adult T cell leukemia (ATL).Sources

With the National Hospital Organization concluded a joint development agreement with the goal of obtaining approval to manufacture and sell as a regenerative medicinal product ATL-DC-101, a dendritic cell vaccine for adult T cell leukemia (ATL).Sources

Integrated Osaka Cell Culture Processing Facility into Shin-Yokohama Cell Culture Processing Facility, and signed absorption merger agreement between subsidiary Medical Business Management Institute Inc. and MedCell Inc. (effective October 1st).Sources

Integrated Osaka CPC into Shin-Yokohama CPC.Sources

Conducted an absorption-type merger of two consolidated subsidiaries, Institute of Medical Service Management, Inc. and MEDcell Co., Ltd. The merger took effect on October 1, 2018.Sources

Signed a contract with JUNTEN BIO Inc. for development of manufacturing technology for regenerative medicine products.Sources

Signed a contract development agreement with JUNTEN BIO Co.,Ltd. for technology to manufacture regenerative medicinal products.Sources

Signed a licensing agreement with US BioLegend Inc.Sources

Concluded a licensing agreement with BioLegend, Inc., headquartered in the US, for the development of research products using one of our novel monoclonal antibodies.Sources

Concluded a licensing agreement with BioLegend, Inc., which is headquartered in the US, for the development of research products using one of our novel monoclonal antibodies.Sources

Integrated the Shin-Yokohama Cell Culture Processing Facility into the Shinagawa Cell Culture Processing Facility (Shinagawa CPF).Sources

Integrated Shin-Yokohama CPC into Shinagawa CPF.Sources

Relocated headquarters to Heiwajima, Ota-ku, Tokyo.Sources

Relocated its Head Office to Heiwajima, Ota-ku, Tokyo.Sources

Signed a licensing agreement for our gamma delta T cell culture processing technology with Taiwan Medigen Biotechnology Corp.Sources

Entered into a joint research agreement with the National Cancer Center Japan.Sources

Signed a licensing agreement with Taiwanese listed biopharmaceutical company Medigen Biotechnology Corp. regarding gamma-delta T cell culture technology.Sources

Signed a joint research agreement with the National Cancer Center.Sources

Signed a joint research agreement with Kyoto Prefectural University of Medicine and filed a joint patent application.Sources

Entered into a joint research agreement with Kyushu University.Sources

Signed a joint research agreement with the Kyoto Prefectural University of Medicine and patent joint application.Sources

Signed a joint research agreement with National University Corporation Kyushu University.Sources

Obtained manufacturing license for regenerative medicine products at Shinagawa CPF.Sources

Obtained license for the manufacture of regenerative medicinal products in Shinagawa CPF.Sources

Transitioned from the Tokyo Stock Exchange Mothers Market to the Growth Market following a review of market classification.Sources

Transitioned from Tokyo Stock Exchange Mothers market to Growth market due to the new market classification of the Tokyo Stock Exchange.Sources

Started providing NKT cell-activating dendritic cell processing technology.Sources

Started providing processing technology for NKT cell-activated dendritic cells.Sources

§07

News

0 ARTICLES

There is no news.

§08

Public records

GOV
National Tax Agency basic information1020001039274
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
株式会社メディネット
Trade name (kana)
メディネット
Name in English
Corporation type
301
Address
〒140-0012 東京都品川区勝島1丁目5番21号
Postal code
1400012
Prefecture code
13
City code
109
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2015-10-05
Update date
2019-06-12
Change date
2019-06-04
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
12
Correction type
0
Trade name image ID
Address image ID
Sequence number
1412918
METI gBizINFO1020001039274
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
1020001039274
Trade name
株式会社メディネット
Trade name (kana)
メディネット
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address
東京都品川区勝島1丁目5番21号
Postal code
1400012
Prefecture
東京都
Prefecture code
13
City or district
品川区
City code
109
Street address
勝島1丁目5番21号
Organisation type
301
Processing type
12
Correction type
0
Status
Representative
代表取締役社長 久布白 兼直
Capital
5102250000
Employees
116
Employees (male)
61
Employees (female)
55
Business summary
医療機関や製薬企業から再生・細胞医療に用いる細胞の加工等を受託する細胞加工業と大学や研究機関との共同研究や国内外の企業とのアライアンスを通じた再生医療等製品の開発・収益化を行う再生医療等製品事業を展開
Website URL
http://www.medinet-inc.co.jp/
Year founded
Business category
R:サービス業(他に分類されないもの)
Date established
1995-10-17
Unified government qualification - grade
|C|C|
Unified government qualification - business items
222|229|315
Update date
2019-06-12
Key information
1020001039274
§09

Sources & updates

SOURCES
↑